AIDS

1. GENER AR
   Balanced HPV vaccination campaigns should include all sexes, genders before and after commencement of sexual activity.
   AIDS. 2025;39:1661-1662.
   

   >> Share

   
   

   
   Ann N Y Acad Sci

2. WILLEMSEN L, Serafini C, Butler J, Ergun S, et al
   Polarization in the COVID-19 pandemic: The impact of vaccination status and conspiracy theories.
   Ann N Y Acad Sci. 2025 Aug 4. doi: 10.1111/nyas.15408.
   

   >> Share

   
   

   
   BMJ

3. TANNE JH
   Robert F Kennedy Jr pulls funding for mRNA vaccine research.
   BMJ. 2025;390:r1664.
   

   >> Share

   
   
4. BOWIE K
   Measles and MMR: Do I need another vaccine?
   BMJ. 2025;390:r1632.
   

   >> Share

   
   
5. O'DOWD A
   Gonorrhoea vaccine rollout aims to save NHS millions and combat soaring cases.
   BMJ. 2025;390:r1636.
   

   >> Share

   
   
6. FREEMAN-ROMILLY N, Lord E, Pollock K
   Gonorrhoea vaccination strategies should take into account all at risk and the potential for severe sequelae in women.
   BMJ. 2025;390:r1539.
   

   >> Share

   
   

   
   Indian Pediatr

7. AGARWAL A, Sajlan S, Chawla R, Mathur SB, et al
   Erratum: Seroprevalence of Hepatitis A in Non-vaccinated Adolescents Aged 9 to 12 Years in New Delhi, India: A Cross-Sectional Study.
   Indian Pediatr. 2025 Aug 6. doi: 10.1007/s13312-025-00165.
   

   >> Share

   
   
8. KASI SG, Dhir SK
   Cocooning Vaccination Strategy for Infants.
   Indian Pediatr. 2025 Aug 6. doi: 10.1007/s13312-025-00149.
   

   >> Share

   
   

   
   J Infect Dis

9. SAMANDARI T, Achola M, Hutter JN, Mboya G, et al
   Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults.
   J Infect Dis. 2025 Aug 2:jiaf398. doi: 10.1093.
   

   >> Share

   
   
10. ZIELINSKI L, Andrejko K, Shang N, Park S, et al
    Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Pneumonia Hospitalization Among Medicare Beneficiaries Aged >/=65 in Long-Term Care.
    J Infect Dis. 2025 Aug 2:jiaf405. doi: 10.1093.
    

    >> Share

    
    

    
    J Virol

11. BAI Y-Z, Xu H, Liu Y-G, Sun Y, et al
    Nsp2 replicase-mediated viral uncoating in porcine alveolar macrophages contributes to the attenuation of PRRSV-2 live attenuated vaccine.
    J Virol. 2025 Aug 4:e0063625. doi: 10.1128/jvi.00636.
    

    >> Share

    
    
12. YU R, Bai Y, Zhang L, Zhou P, et al
    Single self-cleaving mRNA vaccine expressing multiple viral structural proteins elicits robust immune responses and protects nursing piglets against PDCoV infection.
    J Virol. 2025 Aug 6:e0084925. doi: 10.1128/jvi.00849.
    

    >> Share

    
    

    
    JAMA

13. SCHNEIDER L
    Study: No Link Between Aluminum in Childhood Vaccines and Chronic Disorders.
    JAMA. 2025 Aug 8. doi: 10.1001/jama.2025.10992.
    

    >> Share

    
    

    
    Lancet

14. LARSON HJ, Piatek SJ
    A crisis of credibility: the global cost of US vaccine misinformation.
    Lancet. 2025 Jul 30:S0140-6736(25)01495-3. doi: 10.1016/S0140-6736(25)01495.
    

    >> Share

    
    

    
    MMWR Morb Mortal Wkly Rep

15. RODRIGUEZ RM, Torres JR, Chinnock B, Kean E, et al
    Emergency Department Survey of Vaccination Knowledge, Vaccination Coverage, and Willingness to Receive Vaccines in an Emergency Department Among Underserved Populations - Eight U.S. Cities, April-December, 2024.
    MMWR Morb Mortal Wkly Rep. 2025;74:456-462.
    

    >> Share

    
    

    
    Pediatr Infect Dis J

16. TOP KA, Shulha HP, Hassan F, Sauve L, et al
    Epidemiology of Febrile Seizures During the Covid-19 Pandemic: A Canadian Immunization Monitoring Program-Active (IMPACT) Study.
    Pediatr Infect Dis J. 2025;44:e230-e233.
    

    >> Share

    
    

    
    Pediatrics

17. BODY A, Lal L, Downie P, Anazodo A, et al
    Immune Response to COVID-19 Vaccination in Children With Cancer.
    Pediatrics. 2025 Aug 8:e2024070209. doi: 10.1542/peds.2024-070209.
    

    >> Share

    
    

    
    PLoS One

18. ILYASOVA AA, Queen TL, Gilkey M, Fogel BN, et al
    Use of presumptive recommendations and other strategies to encourage HPV vaccine uptake: Results from a national survey of primary care health professionals.
    PLoS One. 2025;20:e0327872.
    

    >> Share

    
    
19. XIA D, Su Y, Song M, Zhu T, et al
    The influence of audience's regulatory focus on the persuasive effect of different pro-vaccine messages.
    PLoS One. 2025;20:e0328638.
    

    >> Share

    
    
20. FERCHIOU A, Giacomini A, Herman N, Lhermie G, et al
    Economics of vaccination against diarrhoea and respiratory diseases in French cow calves' systems: A modelling approach.
    PLoS One. 2025;20:e0329325.
    

    >> Share

    
    
21. MOHAMED PAUZI MH, Abdul Kadir A, Muhamad R, Mat Yudin Z, et al
    A qualitative study on barriers and facilitators of COVID-19 vaccination during pregnancy among pregnant women in Malaysia.
    PLoS One. 2025;20:e0329895.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

22. MCGUIRE DJ, Akondy RS, Yang S, Edupuganti S, et al
    Regulation of CD45 isoforms during human effector and memory CD8 T cell differentiation: Implications for T cell nomenclature.
    Proc Natl Acad Sci U S A. 2025;122:e2322982122.
    

    >> Share

    
    
23. HSU CC, Chamblee M, Ye C, Shamseldin MM, et al
    Intranasal measles virus- and mumps virus-based SARS-CoV-2 vaccine candidates prevent SARS-CoV-2 infection and transmission.
    Proc Natl Acad Sci U S A. 2025;122:e2506821122.
    

    >> Share

    
    

    
    Vaccine

24. SCHUE JL, Miller ES, Fesshaye B, Singh P, et al
    COVID-19 vaccine attitudes, beliefs, intentions and behaviors among pregnant women within the context of dynamic national policy recommendations in Brazil, Ghana, Kenya, and Pakistan.
    Vaccine. 2025 Aug 6:127595. doi: 10.1016/j.vaccine.2025.127595.
    

    >> Share

    
    
25. CHAN YT, Chair SY, Gao RT, Ng MH, et al
    Retraction notice to "Effect of vaccine education intervention on vaccine uptake and vaccine knowledge among older adults: A systematic review with meta-analysis" [Vaccine 56 (2025) 127182].
    Vaccine. 2025 Aug 6:127570. doi: 10.1016/j.vaccine.2025.127570.
    

    >> Share

    
    
26. SIU JY
    Barriers to COVID-19 vaccinations and moral struggle among nurses in a Chinese community: A critical medical anthropology analysis.
    Vaccine. 2025;62:127574.
    

    >> Share

    
    
27. JARVI SI, Osuna A, Pitt WC, Farias M, et al
    Efficacy of a PP2A vaccine for Angiostrongylus costaricensis against rat lungworm disease caused by Angiostrongylus cantonensis in wild-caught rats (Rattus rattus) in Hawaii.
    Vaccine. 2025;62:127532.
    

    >> Share

    
    
28. LIDSTROM AK, Albinsson B, Sund F, Lindback J, et al
    Adverse drug reactions following SARS-CoV-2 vaccination of 3805 healthcare workers cause substantial sick-leave and are correlated to vaccine regimen, age, sex and serological response.
    Vaccine. 2025;62:127553.
    

    >> Share

    
    
29. THORN N, Karampatsas K, Le Doare K, Heath PT, et al
    Progress towards a Group B streptococcal vaccine - where are we now?
    Vaccine. 2025;62:127575.
    

    >> Share

    
    
30. MACKE CA, Carreon SA, Desai KR, Minard CG, et al
    COVID-19 vaccine uptake and attitudes in emerging adults with type 1 diabetes.
    Vaccine. 2025 Apr 6:127083. doi: 10.1016/j.vaccine.2025.127083.
    

    >> Share

    
    
31. RONG Z, Jiao M, Tian L, Wang X, et al
    PRRSV vector vaccine based on VEEV-VSVG recombinant replicon elicits efficient immune responses in piglets.
    Vaccine. 2025;62:127572.
    

    >> Share

    
    
32. CARLTON JG, Pamba D, Ryan N, Olomi W, et al
    Facilitators and barriers to implementation of HPV vaccination in Tanzania: a mixed-methods study exploring perspectives from national, subnational, and community stakeholders, 2018-2023.
    Vaccine. 2025;62:127560.
    

    >> Share

    
    
33. MORO PL, Getahun A, Romanson B, Marquez P, et al
    Safety monitoring of Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System (VAERS), 2023-2024, United States.
    Vaccine. 2025;62:127497.
    

    >> Share

    
    
34. CHOI WS, Lee J, Ottaviano C, Samson S, et al
    Immunogenicity and safety of quadrivalent recombinant influenza vaccine in Korean adults: Phase III, randomized study.
    Vaccine. 2025;62:127521.
    

    >> Share

    
    
35. AUTHIE P, Souque P, Moncoq F, Noirat A, et al
    Lentiviral vector-based T-cell vaccines against Zika and yellow fever viruses.
    Vaccine. 2025;62:127563.
    

    >> Share

    
    
36. LIU R, Patel A, Liu H, Du X, et al
    Influenza vaccination in patients with heart failure compared to usual practice: A model-based cost-effectiveness analysis.
    Vaccine. 2025;62:127566.
    

    >> Share

    
    
37. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 ope
    Vaccine. 2025;62:127562.
    

    >> Share

    
    
38. SAVAS LS, Cuccaro P, Zhang K, Hernandez R, et al
    Factors influencing COVID-19 vaccine uptake among vulnerable communities in Texas: Perceptions of 2-1-1 helpline callers.
    Vaccine. 2025;60 Suppl 1:127554.
    

    >> Share

    
    
39. KISHINO H, Inoue S, Matsuoka O, Yagi M, et al
    A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naive Japanese adults >/=65 years of age.
    Vaccine. 2025;62:127456.
    

    >> Share

    
    
40. XU S, Sy LS, Contreras R, Powers DA, et al
    Differences in COVID-19 XBB.1.5 vaccination coverage: A decomposition analysis across racial and ethnic groups in a large U.S. healthcare system.
    Vaccine. 2025;62:127577.
    

    >> Share

    
    
41. OSMENAJ T, van Roon A, Labuschagne L, Pijpers J, et al
    Determinants for not keeping up to date with COVID-19 vaccination in the 2023 vaccination round among medical risk groups, the Netherlands.
    Vaccine. 2025;62:127561.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share